InvestorsHub Logo
Followers 231
Posts 34993
Boards Moderated 1
Alias Born 11/19/2003

Re: RCH68 post# 956

Sunday, 07/20/2014 11:03:07 PM

Sunday, July 20, 2014 11:03:07 PM

Post# of 2206

Following review of data from the first patient treated with TT-034 on 29 May 2014, the independent DSMB has recommended that the study can continue without modification.

The first patient dosed in the trial has to date experienced no treatment-related adverse effects. Liver biopsy results from the first patient were encouraging and in line with expectations. TT-034 DNA and short hairpin RNA (shRNA) were both detected in the biopsy at sub-therapeutic levels, indicating that liver *transduction occurred.


*Transduction








.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BNTC News